Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria

Full metadata record
DC FieldValueLanguage
dc.contributorLab. Desenvolvimento de Vacinaspt_BR
dc.contributor.authorSantos, Carina Carvalho dospt_BR
dc.contributor.authorRodríguez, Duniapt_BR
dc.contributor.authorKanno, Alex Issamupt_BR
dc.contributor.authorLeite, Luciana Cezar de Cerqueirapt_BR
dc.contributor.authorNascimento, Ivan Pereirapt_BR
dc.identifier.citationSantos CCD, Rodríguez D, Kanno AI, Leite LCC, Nascimento IP. Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria. Hum. Vaccin. Immunother.. 2020;16(3):673-683. doi:10.1080/21645515.2019.1669414.pt_BR
dc.description.abstractThe development of more effective vaccines against Mycobacterium tuberculosis has become a world priority. Previously, we have shown that a recombinant BCG expressing the LTAK63 adjuvant (rBCG-LTAK63) displayed higher protection than BCG against tuberculosis challenge in mice. In order to elucidate the immune effector mechanisms induced by rBCG-LTAK63, we evaluated the immune response before and after challenge. The potential to induce an innate immune response was investigated by intraperitoneal immunization with BCG or rBCG-LTAK63: both displayed increased cellular infiltration in the peritoneum with high numbers of neutrophils at 24 h and macrophages at 7 d. The rBCG-LTAK63-immunized mice displayed increased production of Nitric Oxide at 24 h and Hydrogen Peroxide at 7 d. The number of lymphocytes was higher in the rBCG-LTAK63 group when compared to BCG. Immunophenotyping of lymphocytes showed that rBCG-LTAK63 immunization increased CD4+ and CD8+ T cells. An increased long-term Th1/Th17 cytokine profile was observed 90 d after subcutaneous immunization with rBCG-LTAK63. The evaluation of immune responses at 15 d after challenge showed that rBCG-LTAK63-immunized mice displayed increased TNF-a-secreting CD4+ T cells and multifunctional IL-2+ TNF-a+ CD4+ T cells as compared to BCG-immunized mice. Our results suggest that immunization with rBCG-LTAK63 induces enhanced innate and long-term immune responses as compared to BCG. These results can be correlated with the superior protection induced against TBpt_BR
dc.description.sponsorship(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulopt_BR
dc.relation.ispartofHuman Vaccines & Immunotherapeuticspt_BR
dc.rightsOpen accesspt_BR
dc.titleRecombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteriapt_BR
dc.rights.licenseCC BY-NC-NDpt_BR
dc.contributor.external(USP) Universidade de São Paulopt_BR
dc.subject.keywordrecombinant BCGpt_BR
dc.subject.keywordinnate immunitypt_BR
dc.subject.keywordlong-term immunitypt_BR
dc.relation.ispartofabbreviatedHum Vaccin Immunotherpt_BR
dc.identifier.citationabntv. 16, n. 3, p. 673-683, 2020pt_BR
dc.contributor.butantanSantos, Carina Carvalho Dos|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:PrimeiroAutorpt_BR
dc.contributor.butantanRodríguez, Dunia Del Carmen|:Pesquisador|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanKanno, Alex Issamu|:Aluno|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.contributor.butantanLeite, Luciana Cezar de Cerqueira|:Pesquisador|:Laboratório de Desenvolvimento de Vacinas|:Autor de correspondênciapt_BR
dc.contributor.butantanNascimento, Ivan Pereira|:Pesquisador|:Laboratório de Desenvolvimento de Vacinas|:pt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2017/24832-6pt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2014/01271-0pt_BR
item.fulltextCom Texto completo-
Appears in Collections:Artigos de periódicos

Files in This Item:

Size: 2.64 MB
Format: Adobe PDF
Show simple item record

This item is licensed under a Creative Commons License Creative Commons